NCT02551172View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

PHASE3UnknownINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Hyperlipidemias
Interventions
DRUG

HCP1105

Rosuvastatin + Omega-3-acids ethyl esters

DRUG

HGP0816

Rosuvastatin

DRUG

Placebo of HCP1105

Soybean Oil

DRUG

Placebo of HGP0816

Exclusion of Rosuvastatin in HGP0816

Trial Locations (1)

139-711

RECRUITING

Euljii General Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02551172 - Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD | Biotech Hunter | Biotech Hunter